Sodium-glucose cotransporter-2 inhibitors in cancer patients with type 2 diabetes and established immune checkpoint inhibitor-related cardiotoxicity: a retrospective analysis - Summary - MDSpire
Advertisement
Sodium-glucose cotransporter-2 inhibitors in cancer patients with type 2 diabetes and established immune checkpoint inhibitor-related cardiotoxicity: a retrospective analysis
To investigate the association of SGLT2i use with all-cause mortality, iRCs severity, and major adverse cardiovascular events (MACE) in cancer patients with T2DM who developed iRCs during ICI therapy.
Key Findings:
SGLT2i use was independently associated with reduced all-cause mortality (adjusted HR = 0.520, 95% CI: 0.285–0.947, p = 0.033).
SGLT2i group had longer median survival time (743 days vs. 494 days).
SGLT2i group showed lower proportion of high-grade iRCs (19.2% vs. 45.8%, p = 0.031).
No significant difference in MACE incidence between groups (19.2% vs. 33.3%, p = 0.271).
Interpretation:
SGLT2i use in cancer patients with T2DM and established iRCs is linked to lower all-cause mortality and reduced severity of iRCs, suggesting potential cardioprotective and oncologic benefits, warranting further prospective validation.
Limitations:
Retrospective design may introduce bias, including selection bias.
Single-center study limits generalizability.
Small sample size may affect statistical power.
Conclusion:
SGLT2i use is associated with improved survival and reduced iRC severity in cancer patients with T2DM, warranting further prospective validation to confirm these findings.
